Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click ...

We recently compiled a list of the 10 Best Guru Stocks To Buy Now. In this article, we will have a look at where Roivant ...

Selling plaque psoriasis drug Vtama to Organon looks like another win for Roivant, which has been buying overlooked drugs, ...

As part of the acquisition, Organon will acquire psoriasis treatment Vtama, which could soon be approved in atopic dermatitis ...

Organon & Co (NYSE:OGN) has agreed to acquire Roivant Sciences Ltd’s (NASDAQ:ROIV) Dermavant Sciences Ltd, which is focused ...

The deal hands Organon a psoriasis and eczema cream called Vtama, while Roivant will get more cash to fund its R&D plans.

Goldman Sachs analyst Chris Shibutani has maintained their bullish stance on ROIV stock, giving a Buy rating today. Chris Shibutani has given ...

Roivant executives believe that mosliciguat, administered once per day using a dry powder inhaler, will help fill "an unmet ...

On Wednesday, Roivant Sciences (NASDAQ:ROIV) shares maintained a Buy rating from TD Cowen, following the announcement of a significant licensing agreement with Organon. The deal, which involves ...

Roivant Sciences has licensed worldwide rights to develop and commercialize Bayer's mosliciguat for an upfront payment of $14 ...

On Thursday, Goldman Sachs maintained its Buy rating and $17.00 price target on shares of Roivant Sciences (NASDAQ:ROIV). The firm's positive stance comes after Roivant Sciences announced a ...